20

Conference Chairs Prof. Dr. Angelika Eggert Chair, GPOH Neuroblastoma Study Group Charité University Medicine Berlin Campus Virchow Klinikum

Prof. Dr. Dominique Valteau-Couanet President, SIOPEN Institute Gustave Roussy Paris

Organization:

B. Kömür/Ch. Guirassy

GPOH-Office: G. Mechelk/L. Wünschel

Klinik für Pädiatrie m.S. Onkologie & Hämatologie

Charité, Campus Virchow Klinikum

Augustenburger Platz 1, 13353 Berlin

Fon: +49 30/450-566 132

Fax: +49 30/450-566 906

E-Mail: kinderonkologie@charite.de

1st SIOPEN/GPOH Neuroblastoma Research Symposium

and SIOPEN AGM

October 25 - 27, 2017

Langenbeck Virchow Haus, Berlin, Germany

2

Dear Colleagues and Friends,

we are delighted to welcome you to the 1st International SIOPEN/GPOH Symposium

for Neuroblastoma Research & SIOPEN Annual General Meeting 2017. We are look-

ing forward to a historic meeting laying the official foundation for future joint clini-

cal trials of the two trial groups. We are very happy to welcome the SIOPEN commu-

nity for the first time in Berlin! This beautiful and historic city is not only the capital

of Germany, but it is also the birthplace of neuroblastoma first described by Ru-

dolph Virchow in 1864. For this reason, we decided to host the Welcome Reception

in the historic Virchow lecture hall including a tour of the Museum of Medical Histo-

ry with the Virchow collection on display. We are extremely grateful to the Program

Committee and the SIOPEN EC for their dedication, enthusiasm, and expert advice.

They have developed a truly integrative program that captures the breadth and

depth of neuroblastoma research and emphasizes the critical role of convergent

science in translating research for clinical benefit. Presentations will cover the latest

basic, translational and clinical neuroblastoma research including important topics

such as tumor evolution, liquid biopsies and new drugs. There are numerous oppor-

tunities for attendees to present their work, make fruitful connections, and engage

in dialogue with colleagues and thought leaders from around the world. From the

55 abstracts received, we were able to accommodate 11 abstracts as short oral

presentations throughout the scientific program. All abstracts will be displayed as

posters. We feel confident that you will leave the meeting with a renewed sense of

energy, inspiration, and focus on your neuroblastoma work.

We look forward to meeting you in person, and to discuss many interesting research

topics and clinical questions!

Sincerely yours,

Angelika Eggert, Chair, GPOH neuroblastoma trial group

Dominique Valteau-Couanet, President, SIOPEN trial group

19

Veranstalter und Organisator: GPOH e.V. und SIOPEN

Wissenschaftliche Leitung: Prof. Dr. Angelika Eggert

Prof. Dr. Dominique Valteau-Couanet

Tagungsdatum: 25.-27.10.2017

Tagungsort:

Langenbeck Virchow Haus Luisenstr. 58/59 10117 Berlin

Teilnahmegebühren: 60,- €

Anmeldung unter:

http://members.siopen.org/page-1778036

Zertifizierung für Ärzte (CME):

Die Zertifizierung der Veranstaltung ist bei der Ärztekammer beantragt.

Quellen für Bilder u. Grafiken:

Titelbild: https://de.fotolia.com/id/57185897

Brauhaus Lemke am Alex

Charité Berlin

Sponsor: EUSA Pharma, 17.000 € zzgl. USt.

http://members.siopen.org/EmailTracker/LinkTracker.ashx?linkAndRecipientCode=iNduHZlXiHmlpZEkqwLWo%2fV0fRu0d16J96yrUMsjBBRSZHR8IeL2YU5RdhpTd3NYpvYlWTG%2fdYaCRfwO6NLx5TD%2bGw%2fReoXwMKNUrDqf2cY%3dhttps://de.fotolia.com/id/57185897

18

Langenbeck Virchow Haus

Luisenstr. 58/59

10117 Berlin

X X

Langenbeck Virchow

Haus

Welcome Reception

3

1st SIOPEN/GPOH Neuroblastoma Research Symposium

Langenbeck Virchow Haus, Berlin, Germany

Wednesday, Oct 25th - Translational Neuroblastoma Research

(Lecture Hall)

09.00 h - 09.30 h Registration, Coffee and Poster Setup

09.30 h Welcome A. Eggert, Berlin/D. Valteau-Couanet, Paris

09.35 h - 10.50 h Molecular Risk Stratification

Chairs: K. de Preter, Ghent/F. Westermann, Heidelberg

09.35 h - 09.50 h

Molecular characterization of neuroblastoma for risk stratification and clinical

decision making

G. Schleiermacher, Paris

09.50 h - 10.05 h

Risk stratification of non-HR neuroblastoma according to gene expression

classification

C. Rosswog, Cologne

10.05 h - 10.20 h

Identification of ultra-HR patients using copy number alterations

K. de Preter, Ghent

10.20 h - 10.35 h

Identification of ultra-HR patients using gene expression profiling

M. Capasso, Napels

4

10.35 h - 10.50 h

Definition of risk groups according to telomere maintenance and RAS/p53 pathway mutations

S. Ackermann/M. Fischer, Cologne

10.50 h - 12.05 h Liquid Biopsies

Chairs: S. Burchill, Leeds/H. Deubzer, Berlin

10.50 h - 10.55 h

Introduction to Liquid Biopsies

S. Burchill, Leeds

10.55 h - 11.15 h Keynote Lecture

Measurement and role of ctDNA in diagnostics and monitoring of neuroblastoma

G. Schleiermacher, Paris

11.15 h - 11.30 h

cfDNA/ddPCR defined targets and blood metabolites in neuroblastoma

H. Deubzer, Berlin/M. Lodrini, Berlin

11.30 h - 11.45 h

Disease monitoring based on mRNA measurements in liquid biopsies

S. Burchill, Leeds

11.45 h - 11.55 h Free Paper

Prognostic value of residual tumor cells after induction chemotherapy in the bone marrow of stage M neuroblastoma patients and its relation to tumor genetics: A SIOPEN Biology and Bone Marrow study

S. Fiedler, Vienna

17

Thursday, Oct 26th

20.00 h Dinner: Berlin Beer Brewery: Beer Tasting and Typical Berlin Dinner

(Schnitzel, Currywurst…), Life Music + Dance

Ticket: 50,- € (sold out)

Brauhaus Lemke am Alex Karl-Liebknecht-Str. 13 10178 Berlin

Referents and Chairs:

S. Ackermann, Cologne

P. Ambros, Vienna

J. Anderson, London

M. Arsenian, Stockholm

S. Ash, Tel Aviv

G. Barone, London

K. Beiske, Oslo

C. Beltinger, Ulm

T. Boterberg, Ghent

S. Burchill, Leeds

A. Cañete, Valencia

M. Capasso, Napels

R. Castellani, Milan

L. Chen, Newcastle

L. Chesler, London

O. Cormac, Dublin

K. de Preter, Ghent

H. Deubzer, Berlin

S. Durand, Paris

C. Dyberg, Stockholm

A. Eggert, Berlin

J. Park, Seattle

A. Pearson, London

U. Poetschger, Vienna

S. Sarnacki, Paris

G. Schleiermacher, Paris

J. Schulte, Berlin

V. Segura, Valencia

J. Shohet, Houston

S. Sorrentino, Genoa

F. Speleman, Ghent

S. Taschner-Mandl, Vienna

K. Toews, Berlin

T. Trahair, Sydney

D. Tweddle, Newcastle

D. Valteau-Couanet, Paris

L. van Zogchel, Utrecht

R. Versteeg, Amsterdam

F. Westermann, Heidelberg

M. Eilers, Würzburg

M. Fischer, Cologne

M. Gaze, London

R. George, Boston

M. Halasz, Dublin

R. Haupt, Genoa

A. Henssen, Berlin

P. Hundsdörfer, Berlin

I. Janoueix, Paris

P. Kogner, Stockholm

A. Künkele, Berlin

R. Ladenstein, Vienna

P. Lang, Tübingen

H. Lode, Greifswald

M. Lodrini, Berlin

G. Marshall, Sydney

J. Molenaar, Utrecht

L. Moreno, Madrid

M. Morini, Genoa

16

Friday, Oct 27th SIOPEN AGM (Lecture Hall)

08.30 h—15.45 h

08.30 h 10.00 h SIOPEN AGM - Agenda

circulated among the

Members

D. Valteau-Couanet

10.00 h 10.30 h Coffee Break

10.30 h 13.00 h High Risk Session

10.30 h 11.30 h COG HR Strategy J. Park

11.30 h 13.00 h HR-NBL-2 D. Valteau-Couanet

13.00 h 14.00 h Lunch

14.00 h 15.30 h Relapse session

14.00 h 14.45 h New drug development L. Moreno, C. Owens, A. Eggert

14.45 h 15.30 h Relapse strategy A. Eggert, H. Lode, L. Moreno

15.30 h 15.45 h Break

15.30 h 15.45 h Conclusions D. Valteau-Couanet, A. Eggert

5

11.55 h - 12.05 h Free Paper

Liquid biopsies reveal exosomal miRNA modulation in high-risk neuroblastoma

patients after induction therapy

M. Morini, Genoa

12.05 h- 13.00 h Tumor Heterogeneity + Tumor Microenvironment

Chair: A. Eggert, Berlin/P. Ambros, Vienna

12.05 h - 12.10 h Introduction

A. Eggert, Berlin

12.10 h - 12.30 h Keynote lecture

Tumor heterogeneity in neuroblastoma

P. Ambros, Vienna

12.30 h - 12.45 h

Defining molecular heterogeneity by ssRNA-seq

J. Shohet, Houston

12.45 h - 13.00 h

Inflammation in the neuroblastoma microenvironment

P. Kogner, Stockholm

13.00 h - 13.45 h Lunch

13.45 h - 15.20 h Targeting MYCN

Chairs: M. Eilers, Würzburg/M. Arsenian, Stockholm

13.45 h - 14.10 h Keynote Lecture

Role of MYCN in Neuroblastoma

M. Arsenian, Stockholm

6

14.10 h - 14.25 h

Targeting MYCN with Aurora kinase inhibitors

M. Eilers, Würzburg

14.25 h - 14.40 h

Inhibition of MycN protein stability

G. Marshall, Sydney

14.40 h - 14.55 h

Targeting MYCN with a CDK9/2 inhibitor

L. Chesler, London

14.55 h - 15.10 h Free Paper

Targeting MYCN with metronomic therapy inducing senescence in neuroblastoma

S. Taschner-Mandl, Vienna

15.10 h - 15.20 h Free Paper

Spliceosomal components as potential therapeutic targets for the therapy of

children with high-risk MYCN-amplified neuroblastoma

M. Halasz, Dublin

15.20 h - 16.00 h Coffee Break + Poster Viewing

16.00 h - 17.30 h New Immunotherapy Approaches

Chairs: H. Lode, Greifswald/A. Künkele, Berlin

16.00 h - 16.25 h Keynote lecture

CD171-specific CAR-T cells: experience from the Seattle Children’s hospital

J. Park, Seattle

16.25 h - 16.50 h Keynote lecture

GD2-specific CAR-T cells: experience from the UCL Great Ormond Street

J. Anderson, UCL Great Ormond Street Institute of Child Health, London

15

Thursday, Oct 26th

14.00 h – 19.00 h SIOPEN AGM (Lecture Hall)

14.00 h 15.45 h Low and Intermediate Risk Session Chairman:

D. Valteau- Couanet

Speakers

14.00 h 15.30 h LINES (60’)

Opsoclonus Myoclonus - OMS (15’)

NB-SCI Working Group (15')

A. Cañete

G. Schleiermacher

R. Haupt

15.30 h 15.45 h Coffee break

15.45 h 18.00 h High Risk Session Chairman:

D. Valteau- Couanet

Speakers

HR-NBL-1 (60’)

LTI Studies (30’)

VERITAS (5’)

Pilot studies CT+AntiGD2 (30’)

Bioportal (10’)

R. Ladenstein, U. Poetschger

H. Lode

D. Valteau-Couanet

H. Lode

G. Schleiermacher

18.00 h 19.00 h Bioportal (closed) G. Schleiermacher, R. Laden-

stein

14

Thursday, Oct 26th

13.00 h - 14.00 h

Lunch Symposium: Dinutuximab Beta (sponsored by EUSAPHARMA)

13.00 h – 13.15 h

H. Lode, Greifswald:

Management and treatment tolerance of Dinutuximab Beta longterm infusion

13.15 h – 13.30 h

R. Ladenstein, Vienna:

What are the key benefits of Dinutuximab Beta in the first line maintenance setting?

13.30 – 13.45

P. Hundsdörfer, Berlin:

Role of IL2 in treatment tolerance of Dinutuximab Beta

13.45 – 14.00 h

Discussion and questions from the audience

7

16.50 h - 17.05 h

Towards Biomarkers for immunotherapy with dinutuximab

H. Lode, Greifswald

17.05 h - 17.15 h Free Paper

Haploidentical stem cell transplantation and subsequent immunotherapy with

antiGD2 antibody for patients with relapsed metastatic neuroblastoma

P. Lang, Tübingen

17.15 h - 17.25 h Free Paper

Evaluating the role of PD-1/PD-L1 and the influence of PD-1 inhibition on CAR-T-cell therapy efficacy in neuroblastoma

K. Toews, Berlin

17.25 h - 19.00 h New Drug Targets/Drug Development/Early Clinical Trials

Chairs: L. Moreno, Madrid/O. Cormac, Dublin

17.25 h - 17.50 h Keynote Lecture

Drug development in neuroblastoma - can we be faster?

A. Pearson, London

17.50 h - 18.05 h

New methodology for early clinical trials

L. Moreno, Madrid

18.05 h – 18.20 h

Drug targets in relapsed neuroblastoma identified on the INFORM platform

F. Westermann, Heidelberg

18.20 h - 18.35 h

Integration of targeted therapy with immunotherapy

G. Barone, London

8

18.35 h - 18.45 h Free Paper

Rho-associated kinase is a therapeutic target in neuroblastoma

C. Dyberg, Stockholm

18.45 h - 18.55 h Free Paper

In vivo evaluation of the intravenous MDM2-p53 antagonist RO6839921 alone

and in combination with temozolomide in TP53 wild-type orthotopic models of

neuroblastoma

L. Chen, Newcastle

19.00 h - 20.00 h Poster viewing with drinks

13

Thursday, Oct 26th

SIOPEN 2017 Annual General Meeting

08.00 h—09.00 h EC & AB Meeting (closed) - D. Valteau-Couanet

09.00 h – 13.00 h SIOPEN: Specialty Committees/Working Groups/Parallel

Sessions - By invitation only

09.00 h 13.00 h LINES & Neonates A. Cañete Room Rudolf Virchow

2. floor

09.00 h 13.00 h NB-SCI Workshop S. Ash/R. Haupt/

S. Sorrentino/

T. Trahair

Room Werner Körte

1. floor

09.00 h 11.30 h Radiotherapy T. Boterberg Room Bernhard von

Langenbeck

1. floor

09.00 h 11.30 h Surgery S. Sarnacki Room Emil von Behring

4. floor

09.00 h 11.30 h Molecular Monitor-

ing & Biology Joint

Meeting

S. Burchill/

P. Ambros/

G. Schleiermacher

Room Robert Koch

5. floor

11.30 h 12.30 h Radiotherapy &

Surgery Joint

Meeting

T. Boterberg/

S. Sarnacki

Room Bernhard von

Langenbeck

1. floor

11.30 h 12.30 h Nuclear Medicine R. Castellani Room Emil von Behring

4. floor

11.30 h 13.00 h Molecular Monitor-

ing

S. Burchill/

K. Beiske

Room Robert Koch

5. floor

12.30 h 13.00 h VERITAS joint

meeting with radio-

therapy

D. Valteau-

Couanet/M. Gaze

Room Bernhard von

Langenbeck

1. floor

12

12.20 h - 12.35 h

ALK inhibitor combinations & clinical aspects

D. Tweddle, Newcastle

12.35 h - 12.50 h

Heterogeneity and dynamics of ALK mutations

S. Durand, Paris

12.50 h - 13.00 h Free Paper

Circulating tumor DNA for disease monitoring in neuroblastoma

L. van Zogchel, Utrecht

9

Berliner Medizinhistorisches Museum der Charité Campus Charité Mitte Charitéplatz 1 10117 Berlin

20.00 h Welcome Reception - Historical Virchow Lecture Hall, Charité Mitte

with Guided Tour: Museum of Medical History

Prior Registration needed due to limited space!!

10

Thursday, Oct 26th Basic/Translational Research (Plenary Hall)

Clinical Research/SIOPEN AGM

08.00 h - 09.00 h EC & AB SIOPEN Meeting (closed) - D. Valteau-Couanet, Paris

08.00 h - 09.00 h Registration open

08.30 h - 10.00 h Neuroblastoma Pathogenesis

Chairs: R. Versteeg, Amsterdam/F. Speleman, Ghent

08.30 h - 09.00 h Keynote Lecture

The split personality of neuroblastoma

R. Versteeg, Amsterdam

09.00 h - 09.15 h

Deciphering super-enhancer landscape, transcriptional circuitries and cell identity in neuroblastoma

I. Janoueix, Paris

09.15 h - 09.30 h

Vulnerabilities of neuroblastoma defined by core transcriptionally regulatory

circuitries

F. Westermann, Heidelberg

09.30 h - 09.45 h

Copy number driven dependency genes implicated in core regulatory circuits and cellular states in neuroblastoma

F. Speleman, Ghent

09.45 h - 09.55 h Free Paper

Synthetic lethal targeting of PGBD5-induced DNA repair dependency in

neuroblastoma

A. Henssen, Berlin

11

09.55 h - 10.05 h Free Paper

Metabolome of childhood neuroblastoma: a pilot model

V. Segura, Valencia

10.05 h - 11.00 h New Preclinical Models: PDX, GEMM, zebrafish

Chairs: L. Chesler, London/C. Beltinger, Ulm)

10.05 h - 10.30 h Keynote Lecture

Neuroblastoma mouse models

L. Chesler, London

10.30 h - 10.45 h

Imaging studies of neuroblastoma GEMM and PDX models

C. Beltinger, Ulm

10.45 h - 11.00 h

Zebrafish neuroblastoma modeling: from the tank to the bedside and back

F. Speleman, Ghent

11.00 h - 11.30 h Coffee Break

11.30 h - 13.00 h Targeting RAS/MAPK & ALK

Chairs: J. Schulte, Berlin/R. George, Boston

11.30 h - 11.55 h Keynote Lecture

Targeting RAS/MAPK

J. Molenaar, Utrecht

11.55 h - 12.20 h Keynote Lecture

Targeting ALK

R. George, Boston